A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice
- 15 December 2007
- journal article
- Published by American Society of Hematology in Blood
- Vol. 110 (13) , 4144-4152
Abstract
A longstanding goal for the treatment of hemophilia B is the development of a gene transfer strategy that can maintain sustained production of clotting factor IX (F.IX) in the absence of an immune response. To this end, we have sought to use lentiviral vectors (LVs) as a means for systemic gene transfer. Unfortunately, initial evaluation of LVs expressing F.IX from hepatocyte-specific promoters failed to achieve sustained F.IX expression in hemophilia B mice due to the induction of an anti-F.IX cellular immune response. Further analysis suggested that this may be a result of off-target transgene expression in hematopoietic-lineage cells of the spleen. In order to overcome this problem, we modified our vector to contain a target sequence for the hematopoietic-specific microRNA, miR-142-3p. This eliminated off-target expression in hematopoietic cells, and enabled sustained gene transfer in hemophilia B mice for more than 280 days after injection. Treated mice had more than 10% normal F.IX activity, no detectable anti-F.IX antibodies, and were unresponsive to F.IX immunization. Importantly, the mice survived tail-clip challenge, thus demonstrating phenotypic correction of their bleeding diathesis. This work, which is among the first applications to exploit the microRNA regulatory pathway, provides the basis for a promising new therapy for the treatment of hemophilia B.Keywords
This publication has 52 references indexed in Scilit:
- Gene therapy for hemophiliaCurrent Opinion in Hematology, 2006
- Cellular and genetic therapies for haemophiliaHaemophilia, 2006
- Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune responseNature Medicine, 2006
- Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients?Journal of Thrombosis and Haemostasis, 2005
- Gene therapy for hemophilia: an imperative to succeedJournal of Thrombosis and Haemostasis, 2005
- GENE THERAPY: Twenty-First Century MedicineAnnual Review of Biochemistry, 2005
- Gene therapy for hemophilia? YesJournal of Thrombosis and Haemostasis, 2004
- Efficient Gene Delivery and Targeted Expression to Hepatocytes In Vivo by Improved Lentiviral VectorsHuman Gene Therapy, 2002
- Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapyThe Journal of Gene Medicine, 2000
- Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vectorNature Genetics, 2000